ConductScience.org, home

Paper31270272

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Mestermann K and 9 others. Sci Transl Med, 2019. Cited by 461 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Papers, record 31270272. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31270272

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
PubMed
Journal
Sci Transl Med
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
461
iCite
Relative citation ratio, by iCite
15.4
iCite
Revised in PubMed
2020-09-30
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mestermann KKatrinhttps://orcid.org/0000-0002-3585-5055
2Giavridis TTheodoros
3Weber JJustus
4Rydzek JJulian
5Frenz SSilkehttps://orcid.org/0000-0002-2026-2177
6Nerreter TThomashttps://orcid.org/0000-0002-0493-1369
7Mades AAndreashttps://orcid.org/0000-0001-7322-2817
8Sadelain MMichelhttps://orcid.org/0000-0002-9031-8025
9Einsele HHermann
10Hudecek MMichaelhttps://orcid.org/0000-0002-2280-2202

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DasatinibMajor topic
Protein Kinase InhibitorsMajor topic
Receptors, Antigen, T-CellMajor topic
T-LymphocytesMajor topic
Animals
Cytokine Release Syndrome
Dexamethasone
Female
Humans
Lymphocyte Activation
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
Mice, SCID
Phosphorylation

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in31312040TKI-based on/off switch for CAR T cells.https://conductscience.org/library/papers/31312040PubMed
Comment in31340935CAR T Cells: Hitting the Pause Button.https://conductscience.org/library/papers/31340935PubMed
Comment in31371792Steering CARs in the right direction.https://conductscience.org/library/papers/31371792PubMed

Download CSV of comments and corrections

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19180086HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.Science1997https://conductscience.org/library/papers/9180086PubMed
29857028Generation of destabilized green fluorescent protein as a transcription reporter.J Biol Chem1998https://conductscience.org/library/papers/9857028PubMed
329972754Chimeric Antigen Receptor Therapy.N Engl J Med2018https://conductscience.org/library/papers/29972754PubMed
416740718The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.Cancer Res2006https://conductscience.org/library/papers/16740718PubMed
517429625Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.Cancer Chemother Pharmacol2008https://conductscience.org/library/papers/17429625PubMed
615728125An inducible caspase 9 safety switch for T-cell therapy.Blood2005https://conductscience.org/library/papers/15728125PubMed
727605551Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci Transl Med2016https://conductscience.org/library/papers/27605551PubMed
830573301Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.Mol Ther2019https://conductscience.org/library/papers/30573301PubMed
914965378Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.Hum Gene Ther2004https://conductscience.org/library/papers/14965378PubMed
1026700307Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.PLoS One2015https://conductscience.org/library/papers/26700307PubMed
1130559421Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.Nat Med2019https://conductscience.org/library/papers/30559421PubMed
1228541315Therapeutic T cell engineering.Nature2017https://conductscience.org/library/papers/28541315PubMed
1328925994Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/28925994PubMed
1427760047Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.J Clin Invest2016https://conductscience.org/library/papers/27760047PubMed
1529385376Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385376PubMed
1629808007Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.Nat Med2018https://conductscience.org/library/papers/29808007PubMed
1717310380The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.Cancer Immunol Immunother2007https://conductscience.org/library/papers/17310380PubMed
1829808005CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.Nat Med2018https://conductscience.org/library/papers/29808005PubMed
1918395492The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.Clin Immunol2008https://conductscience.org/library/papers/18395492PubMed
2018420784Metabolism and disposition of dasatinib after oral administration to humans.Drug Metab Dispos2008https://conductscience.org/library/papers/18420784PubMed

See all 25 referencesDownload CSV of references

Cited by308

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 461 citations.

PMIDTitleJournalYearIn PapersSource
42952196BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy.Cancer Sci2026https://conductscience.org/library/papers/42952196PubMed
42921052When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy.ACS Bio Med Chem Au2026https://conductscience.org/library/papers/42921052PubMed
42797493Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42797493PubMed
42756481CAR T-cells for the treatment of CNS malignancies.Front Immunol2026https://conductscience.org/library/papers/42756481PubMed
42681665Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomark Res2026https://conductscience.org/library/papers/42681665PubMed
42665002Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.Prog Biomed Eng (Bristol)2026https://conductscience.org/library/papers/42665002PubMed
42663750CAR-T cell therapy: potential for paediatric brain tumours-an update.J Neurooncol2026https://conductscience.org/library/papers/42663750PubMed
42626063Developing immunotherapies through glycosylation reprogramming to combat solid cancers.Front Immunol2026https://conductscience.org/library/papers/42626063PubMed
42582333Repurposing mitochondrial-targeting drugs for management of ICANS in CAR T-cell therapy: a novel steroid-sparing approach.Front Pharmacol2026https://conductscience.org/library/papers/42582333PubMed
42565078Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells.Mol Ther Adv2026https://conductscience.org/library/papers/42565078PubMed
42555708Dasatinib reversibly disrupts T cell motility and activation in lymph nodes.Sci Adv2026https://conductscience.org/library/papers/42555708PubMed
42496998Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges.Technol Cancer Res Treat2026https://conductscience.org/library/papers/42496998PubMed
42488656CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors.Front Immunol2026https://conductscience.org/library/papers/42488656PubMed
42457686IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia.Nat Commun2026https://conductscience.org/library/papers/42457686PubMed
42454036Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology.Front Immunol2026https://conductscience.org/library/papers/42454036PubMed
42426348Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.Leukemia2026https://conductscience.org/library/papers/42426348PubMed
42380645A bibliometric and visualized analysis of CAR-T or TCR-T in solid tumor (from 2015 to 2024).Discov Oncol2026https://conductscience.org/library/papers/42380645PubMed
42349018Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.Blood Adv2026https://conductscience.org/library/papers/42349018PubMed
42204565Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy.J Transl Med2026https://conductscience.org/library/papers/42204565PubMed
42129307Circadian engineering of in vivo CAR T cell therapy for precision oncology.NPJ Precis Oncol2026https://conductscience.org/library/papers/42129307PubMed

See all 308 cited byDownload CSV of cited by

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CARTPT9607PubTator's text mininghttps://conductscience.org/library/genes/9607NCBI Gene
CASP9842PubTator's text mininghttps://conductscience.org/library/genes/842NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD247919PubTator's text mininghttps://conductscience.org/library/genes/919NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD69969PubTator's text mininghttps://conductscience.org/library/genes/969NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL2RA3559PubTator's text mininghttps://conductscience.org/library/genes/3559NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
LCK3932PubTator's text mininghttps://conductscience.org/library/genes/3932NCBI Gene
MS4A1931PubTator's text mininghttps://conductscience.org/library/genes/931NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
PTPRC5788PubTator's text mininghttps://conductscience.org/library/genes/5788NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene
TNFRSF93604PubTator's text mininghttps://conductscience.org/library/genes/3604NCBI Gene
TRBV20OR9-26962PubTator's text mininghttps://conductscience.org/library/genes/6962NCBI Gene

See all 22 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31270272

GET https://conductscience.org/api/papers/v1/31270272/references?page=2